Mesoblast

Mesoblast EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Mesoblast (MESO) as of Oct 18, 2026 is -51.25 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -62.44 M USD — a change of -17.93% (higher).

EBITDA

-51.25 MUSD

YoY

-17.93%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Mesoblast is 2026 -51.25 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Mesoblast was 2025 -62.44 M USD. It decreases by -17.93% higher compared to the previous year.

The Mesoblast EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
-87.05 M USD
Jan 1, 2020
-72.64 M USD
Jan 1, 2021
-88.92 M USD
Jan 1, 2022
-80.95 M USD
Jan 1, 2023
-62.81 M USD
Jan 1, 2024
-69.31 M USD
Jan 1, 2025
-62.44 M USD
Jan 1, 2026
-51.25 M USD
The Mesoblast EBITDA history
YEAREBITDAYoY
-51.25 MUSD-17.93%
-62.44 MUSD-9.91%
-69.31 MUSD+10.35%
-62.81 MUSD-22.41%
-80.95 MUSD-8.96%
-88.92 MUSD+22.41%
-72.64 MUSD-16.55%
-87.05 MUSD+12.56%
-77.34 MUSD-14.11%
-90.04 MUSD+10.47%
-81.51 MUSD-28.12%
-113.39 MUSD+56.67%
-72.38 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Mesoblast Stock analysis

What does Mesoblast do? Mesoblast Ltd, based in Melbourne, Australia, develops regenerative medicine products using mesenchymal lineage cells. The company focuses on clinical-stage therapies such as Remestemcel-L for inflammatory conditions including graft versus host disease and inflammatory bowel disease, and MPC-300-IV for rheumatoid arthritis. It operates in Australia, the US, Singapore, and Switzerland with 81 employees and is listed on the stock exchange since 2015. Mesoblast is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mesoblast stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Mesoblast is -51.25 M USD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Mesoblast changed from -62.44 M USD to -51.25 M USD, representing a -17.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Mesoblast since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Mesoblast historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Mesoblast

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Mesoblast